Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib

Abstract Background Abivertinib is a novel oral, third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that overcomes T790M‐induced resistance in non‐small cell lung cancer (NSCLC) patients. Here, we report the results of a complete and detailed clinical data of pa...

Full description

Bibliographic Details
Main Authors: Hanping Wang, Ruili Pan, Xiaotong Zhang, Xiaoyan Si, Mengzhao Wang, Li Zhang
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Thoracic Cancer
Subjects:
Abivertinib
osimertinib
sequential treatment
T790M mutation
third‐generation EGFR TKI
Online Access:https://doi.org/10.1111/1759-7714.13302

Internet

https://doi.org/10.1111/1759-7714.13302

Similar Items